Limits...
The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.

Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV - Arab J Urol (2015)

Bottom Line: During treatment with the standard and higher dose of solifenacin, within 8 weeks most variables of the condition of the lower urinary tract reached a normal state or improved.Patients aged >60 years who had been treated for a UTI have a high risk of developing symptoms of an OAB.Solifenacin in standard doses is an efficient and safe means of managing overactive detrusor symptoms after a UTI.

View Article: PubMed Central - PubMed

Affiliation: School of Humanities, Far Eastern Federal University, Russian Federation.

ABSTRACT

Objective: To determine the efficacy and safety of solifenacin for correcting the residual symptoms of an overactive bladder (OAB) in patients who were treated for a urinary tract infection (UTI).

Patients and methods: Using random sampling, 524 patients aged >60 years were selected (347 women, 66.2%, and 177 men, 33.8%). They denied the presence of any symptoms of detrusor overactivity in their medical history, but had a diagnosis of a UTI. At least 1 month after the end of treatment and a laboratory confirmation of the absence of infection, each patient completed an OAB-Awareness Tool questionnaire (OAB signs, total score 8 points), and a noninvasive examination of urinary function (uroflowmetry). Each day patients in group A took solifenacin 10 mg and those in group B took 5 mg, with patients in group C being given a placebo.

Results: During the study 58.8% of patients had symptoms of an OAB at 1 month after the end of the treatment for a UTI, and normal laboratory markers. During treatment with the standard and higher dose of solifenacin, within 8 weeks most variables of the condition of the lower urinary tract reached a normal state or improved.

Conclusion: Patients aged >60 years who had been treated for a UTI have a high risk of developing symptoms of an OAB. Solifenacin in standard doses is an efficient and safe means of managing overactive detrusor symptoms after a UTI.

No MeSH data available.


Related in: MedlinePlus

Distribution of the groups, examinations and treatment. UF, uroflowmetry.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4563008&req=5

f0005: Distribution of the groups, examinations and treatment. UF, uroflowmetry.

Mentions: This was a placebo-controlled longitudinal study in patients aged >60 years who sought medical attention in the Urological Department of the 3rd Municipal Hospital (Vladivostok, Russian Federation) from 1 March to 31 December 2012. For this study, 524 patients (347 women, 66.2%, 177 men, 33.8%) who had been diagnosed with a UTI were selected using blinded random sampling. All of them denied the presence of signs of an OAB in their medical history. The study design is shown in Fig. 1. At least 1 month after the end of treatment, and laboratory confirmation of the absence of UTI (positive urine culture, ⩽105 colony-forming units/mL, a physiologically normal number of white and red blood cells in urine, and normal urine density) each patient completed the OAB-Awareness Tool (AT) questionnaire (OAB signs, total 8 points) [25,26], and had a noninvasive examination of urinary function (uroflowmetry) [27–29]. These results were taken as the baseline and determined the percentage of patients with signs of OAB, and the severity of symptoms. All patients with ОAB symptoms were randomly divided into three groups: A (107 patients, mean age 67.2 years), B (99, 65.9 years) and C (102, 65.1 years). Each day the patients in group A took solifenacin 10 mg, and those in group B 5 mg, with group C taking a placebo. The patients were assessed over 2 months, using urinary diaries, and a final assessment with the OAB-AT questionnaire and uroflowmetry. The efficacy of the treatment was assessed clinically by determining the number of urgency episodes (UE), incontinence episodes (IE), and episodes of daytime urination [30–32]. The second endpoint was a comparison of the conditions of the lower urinary tract (LUT) in the patients of each group after the treatment (see Fig. 2).


The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.

Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV - Arab J Urol (2015)

Distribution of the groups, examinations and treatment. UF, uroflowmetry.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4563008&req=5

f0005: Distribution of the groups, examinations and treatment. UF, uroflowmetry.
Mentions: This was a placebo-controlled longitudinal study in patients aged >60 years who sought medical attention in the Urological Department of the 3rd Municipal Hospital (Vladivostok, Russian Federation) from 1 March to 31 December 2012. For this study, 524 patients (347 women, 66.2%, 177 men, 33.8%) who had been diagnosed with a UTI were selected using blinded random sampling. All of them denied the presence of signs of an OAB in their medical history. The study design is shown in Fig. 1. At least 1 month after the end of treatment, and laboratory confirmation of the absence of UTI (positive urine culture, ⩽105 colony-forming units/mL, a physiologically normal number of white and red blood cells in urine, and normal urine density) each patient completed the OAB-Awareness Tool (AT) questionnaire (OAB signs, total 8 points) [25,26], and had a noninvasive examination of urinary function (uroflowmetry) [27–29]. These results were taken as the baseline and determined the percentage of patients with signs of OAB, and the severity of symptoms. All patients with ОAB symptoms were randomly divided into three groups: A (107 patients, mean age 67.2 years), B (99, 65.9 years) and C (102, 65.1 years). Each day the patients in group A took solifenacin 10 mg, and those in group B 5 mg, with group C taking a placebo. The patients were assessed over 2 months, using urinary diaries, and a final assessment with the OAB-AT questionnaire and uroflowmetry. The efficacy of the treatment was assessed clinically by determining the number of urgency episodes (UE), incontinence episodes (IE), and episodes of daytime urination [30–32]. The second endpoint was a comparison of the conditions of the lower urinary tract (LUT) in the patients of each group after the treatment (see Fig. 2).

Bottom Line: During treatment with the standard and higher dose of solifenacin, within 8 weeks most variables of the condition of the lower urinary tract reached a normal state or improved.Patients aged >60 years who had been treated for a UTI have a high risk of developing symptoms of an OAB.Solifenacin in standard doses is an efficient and safe means of managing overactive detrusor symptoms after a UTI.

View Article: PubMed Central - PubMed

Affiliation: School of Humanities, Far Eastern Federal University, Russian Federation.

ABSTRACT

Objective: To determine the efficacy and safety of solifenacin for correcting the residual symptoms of an overactive bladder (OAB) in patients who were treated for a urinary tract infection (UTI).

Patients and methods: Using random sampling, 524 patients aged >60 years were selected (347 women, 66.2%, and 177 men, 33.8%). They denied the presence of any symptoms of detrusor overactivity in their medical history, but had a diagnosis of a UTI. At least 1 month after the end of treatment and a laboratory confirmation of the absence of infection, each patient completed an OAB-Awareness Tool questionnaire (OAB signs, total score 8 points), and a noninvasive examination of urinary function (uroflowmetry). Each day patients in group A took solifenacin 10 mg and those in group B took 5 mg, with patients in group C being given a placebo.

Results: During the study 58.8% of patients had symptoms of an OAB at 1 month after the end of the treatment for a UTI, and normal laboratory markers. During treatment with the standard and higher dose of solifenacin, within 8 weeks most variables of the condition of the lower urinary tract reached a normal state or improved.

Conclusion: Patients aged >60 years who had been treated for a UTI have a high risk of developing symptoms of an OAB. Solifenacin in standard doses is an efficient and safe means of managing overactive detrusor symptoms after a UTI.

No MeSH data available.


Related in: MedlinePlus